| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Ustekinumab Approved by NICE for Moderate to Severe Plaque Psoriasis NEW YORK -- September 23, 2009 -- The National Institute for Health and Clinical Excellence (NICE) has approved ustekinumab (Stelara) as a treatment option for adults with moderate to severe plaque psoriasis who have not respond to, or have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate, and psoralen plus ultraviolet A light (PUVA). In clinical studies, treatment with ustekinumab demonstrated a significant, visible improvement in patient’s psoriasis with convenient 12 weekly maintenance dosing. This has the potential to give patients with psoriasis greater freedom to live their lives with a significantly reduced burden of disease and without the inconvenience of frequent injections. “Two-thirds of patients taking [ustekinumab] in placebo-controlled trials saw a significant, visible improvement in their psoriasis in as little as 12 weeks,” said Christopher Griffiths, MD, Department of Dermatology, University of Manchester, Manchester, United Kingdom. “This is reflective of what I have seen in clinical practice, with patients experiencing considerable improvements in skin clearance with the added benefit of a convenient dosing regimen.”
SOURCE: Johnson&Johnson
|